The recently released final guidance by the U.S. Food & Drug Administration (FDA) on “Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products” introduces a new framework that is poised to transform the way statistical analyses are conducted in RCTs.
In May 2023, the FDA has unveiled its definitive guidance titled “Adjusting for Covariates in Randomized Clinical Trials (RCT) for Drugs…
Patient adherence remains a significant challenge in clinical research and medical practice, affecting drug development, healthcare costs, and…
Compl-AI is a predictive tool that helps clinical trial sponsors optimize patient recruitment and engagement strategies. Nonadherence in clinical trials and high rates of dropout make efficacy and safety more difficult to determine.
2022 was a year of remarkable success for Cognivia.
Thank you to our team, partners and clients for your continued support! Here are highlights from this year – from exciting company updates to thought leadership articles.
We are proud to be a finalist for the award of ‘Scale-up de l’Année – Scale-up of the…